AVITA Medical Inc (ASX: AVH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AVITA Medical Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $379.64 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 128.53 million
Earnings per share -0.280
Dividend per share N/A
Year To Date Return -27.97%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AVITA Medical Inc (ASX: AVH)
    Latest News

    a woman
    ⏸️ Investing

    Are Avita Medical shares a buy after rocketing 500% YTD?

    The Avita Medical Ltd (ASX: AVH) share price has risen more than 500% since January. Is it a buy?

    Read more »

    a woman
    Share Market News

    High profile fundie warns these 10 ASX shares have "bubble" valuations

    Bubs Australia Ltd (ASX: BUB), Audinate Group Ltd (ASX: AD8) and other popular shares are in the firing line.

    Read more »

    a woman
    Share Fallers

    Why top brokers are urging investors to buy the Nearmap share price dip

    The Nearmap Ltd (ASX: NEA) share price is taking a beating for a second day following the release of its…

    Read more »

    a woman
    Share Gainers

    These All Ordinaries shares have more than tripled in value in 2019

    The AVITA Medical Ltd (ASX:AVH) share price and two others on the All Ords index have more than tripled in…

    Read more »

    a woman
    Share Gainers

    Nearmap and these ASX growth shares have doubled in value in 2019

    The Nearmap Ltd (ASX:NEA) share price and two others have been on fire in 2019. Here's why...

    Read more »

    a woman
    Share Gainers

    Why AVITA, Bubs, Kogan, & Paragon Care shares stormed higher today

    The Bubs Australia Ltd (ASX:BUB) share price and the Kogan.com Ltd (ASX:KGN) share price are two of four storming higher…

    Read more »

    a woman
    Share Gainers

    Why the AVITA Medical share price stormed 6% higher today

    The AVITA Medical Ltd (ASX:AVH) share price has stormed a sizeable 6.5% higher this afternoon after its massive 500% gain…

    Read more »

    a woman
    Share Market News

    Here are the 10 best small-cap shares of 2019

    Should I buy small cap shares or avoid like the plague?

    Read more »

    a woman
    Share Gainers

    Why Bubs and these ASX shares have more than doubled in value in 2019

    The Bubs Australia Ltd (ASX:BUB) share price is one of three rocketing higher in 2019. Here's why...

    Read more »

    a woman
    Share Gainers

    Why the PolyNovo share price has rocketed almost 200% higher in 12 months

    The PolyNovo Ltd (ASX:PNV) share price has almost tripled in value in 12 months. Here's why...

    Read more »

    a woman
    Share Gainers

    ALL ORDINARIES finishes higher Thursday 8 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) and ALL ORDINARIES (Index:^AXAO) (ASX:XAO) finished higher on Thursday.

    Read more »

    a woman
    Share Market News

    Why the AVITA Medical share priced rocketed 16% higher today

    The AVITA Medical Ltd (ASX:AVH) share price has rocketed higher today after a positive announcement. Here's what you need to…

    Read more »

    Frequently Asked Questions

    No, AVITA Medical does not pay dividends at this time.

    AVITA Medical Inc listed on the ASX on 24 June 2020.

    Yes, as well as being listed on the ASX, AVITA Medical Inc is listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AVITA Medical Inc

    AVITA Medical Inc (ASX: AVH) is a healthcare company specialising in regenerative medicine. It is best known for its RECELL system, a burn treatment device that creates 'spray-on skin' from a patient's own skin cells within 30 minutes, avoiding or reducing the need for skin grafts.

    The product was originally invented and patented by Western Australian doctor and clinical professor Fiona Wood in 1993. 

    RECELL is approved for use in Australia, Europe, Canada, China, the Middle East, and Africa. It is also approved for treating adult patients in the US. As well as burns, AVITA Medical has evidence of RECELL's effectiveness for additional skin applications, such as treating chronic and traumatic wounds, scar revision, and vitiligo. 

    AVITA Medical Inc is domiciled and also listed on the US Nasdaq where it trades under the ticker NASDAQ: RCEL.

    AVH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Apr 2024 $3.09 $0.11 3.69% 525,160 $3.10 $3.14 $3.04
    16 Apr 2024 $2.98 $-0.16 -5.10% 761,348 $3.00 $3.08 $2.95
    15 Apr 2024 $3.14 $-0.21 -6.27% 835,926 $3.20 $3.30 $3.14
    12 Apr 2024 $3.35 $-0.63 -15.83% 1,706,763 $3.38 $3.43 $3.17
    11 Apr 2024 $3.98 $-0.52 -11.56% 935,801 $4.01 $4.14 $3.77
    10 Apr 2024 $4.50 $-0.08 -1.75% 87,769 $4.57 $4.57 $4.47
    09 Apr 2024 $4.58 $-0.06 -1.29% 72,998 $4.68 $4.68 $4.58
    08 Apr 2024 $4.64 $0.04 0.87% 23,036 $4.65 $4.70 $4.63
    05 Apr 2024 $4.60 $-0.06 -1.29% 69,103 $4.66 $4.66 $4.55
    04 Apr 2024 $4.66 $0.05 1.08% 64,392 $4.62 $4.66 $4.57
    03 Apr 2024 $4.61 $-0.19 -3.96% 91,966 $4.80 $4.80 $4.60
    02 Apr 2024 $4.80 $-0.15 -3.03% 94,015 $4.92 $4.92 $4.80
    28 Mar 2024 $4.95 $0.03 0.61% 115,914 $4.96 $5.06 $4.92
    27 Mar 2024 $4.92 $0.15 3.14% 58,301 $4.80 $4.95 $4.80
    26 Mar 2024 $4.77 $-0.06 -1.24% 63,157 $4.83 $4.83 $4.77
    25 Mar 2024 $4.83 $-0.15 -3.01% 60,606 $4.85 $4.93 $4.82
    22 Mar 2024 $4.98 $0.14 2.89% 76,236 $4.81 $4.98 $4.81
    21 Mar 2024 $4.84 $0.01 0.21% 79,808 $4.85 $4.90 $4.81
    20 Mar 2024 $4.83 $-0.03 -0.62% 87,103 $4.86 $4.89 $4.78
    19 Mar 2024 $4.86 $-0.24 -4.71% 138,063 $4.89 $4.89 $4.77

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    27 Dec 2023 James Corbett Sell 1,445 $6,025
    As advised by the company. sale of 1,445 Common Stock
    22 Dec 2023 Jeremy Curnock-Cook Sell 2,500 $30,120
    As advised by the company. Sale of Common Stock to satisfy personal tax
    obligations in relation to the vesting of RSUs
    in December 2023.
    13 Dec 2023 Jan Reed Exercise 12,589 $47,334
    Conversion of securities. 11,958 RSUs
    13 Dec 2023 Jan Reed Issued 12,589 $47,334
    Conversion of securities.
    13 Dec 2023 Jeremy Curnock-Cook Issued 12,589 $47,334
    Conversion of securities.
    13 Dec 2023 Jeremy Curnock-Cook Exercise 12,589 $47,334
    Conversion of securities. 6,175 RSUs
    13 Dec 2023 Louis (Lou) Panaccio Exercise 12,589 $47,334
    Conversion of securities. 6,175 RSUs
    13 Dec 2023 Louis (Lou) Panaccio Issued 12,589 $47,334
    Conversion of securities.
    13 Dec 2023 Suzanne Crowe Exercise 12,589 $47,334
    Conversion of securities. 6,175 RSU
    13 Dec 2023 Suzanne Crowe Issued 12,589 $47,334
    Conversion of securities.
    07 Jun 2023 Jeremy Curnock-Cook Issued 6,175 $26,490
    Issue of securities. 18,764 RSUs
    07 Jun 2023 Jeremy Curnock-Cook Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 Suzanne Crowe Issued 6,175 $26,490
    Issue of securities. 18,764 RSUs
    07 Jun 2023 Suzanne Crowe Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 Louis (Lou) Panaccio Issued 6,175 $26,490
    Issue of securities. RSUs 18,764
    07 Jun 2023 Louis (Lou) Panaccio Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 James Corbett Issued 100,000 $429,000
    Issue of options.
    07 Jun 2023 Jan Reed Issued 2,646 $11,351
    Issue of options.
    07 Jun 2023 Jan Reed Issued 6,175 $26,490
    Issue of securities.
    07 Jun 2023 Cary Vance Issued 16,549 $70,995
    Issue of securities. 16,549 RSUs
    07 Jun 2023 Cary Vance Issued 7,092 $30,424
    Issue of options.
    07 Jun 2023 Robert McNamara Issued 7,092 $30,424
    Issue of options.
    07 Jun 2023 Robert McNamara Issued 16,549 $70,995
    Issue of securities. 16,549 RSUs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Louis (Lou) James Panaccio Non-Executive ChairmanNon-Executive Director Jul 2014
    Mr Panaccio is a healthcare businessman with experience leading companies from concept to commercialization. Mr. Panaccio possesses more than 35 years of executive leadership experience in healthcare services and life sciences, including more than 25 years of board-level experience. Mr Panaccio is currently a Director of ASX50 company and one of the medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005.
    Professor Suzanne Crowe Non-Executive Director Jan 2016
    Ms Crowe is a physician-scientist and ASX/Nasdaq-listed company director with expertise in supporting companies with their medical and scientific strategies. A Fellow of the Australian Institute of Company Directors, and Emeritus Professor, Monash University Melbourne, she is currently a Director of Sonic Healthcare Ltd, a global medical diagnostics company. Past board positions include St Vincent's Health Australia Ltd (2012-2021), the country's not-for-profit health and aged care provider. After 35 years at both, she has recently retired from the Burnet Institute, having served as Associate Director Clinical Research, and The Alfred Hospital Melbourne, where she held the appointment of Senior Specialist Physician in Infectious Diseases. She was appointed as Officer of the Order of Australia in June 2020 in recognition of her distinguished services to health, clinical governance, biomedical research, and education.
    Mr Jeremy Curnock-Cook Non-Executive Director Oct 2012
    Mr Curnock-Cook is a veteran in the life sciences/healthcare industry and has been actively supporting the commercialization of healthcare innovations and helping entrepreneurs build their international businesses over the past 45 years. Founder and Managing Director of BioScience Managers, Mr Curnock Cook brings his decades of international experience to our Board of Directors. Over his career, Mr Curnock Cook has managed more than US $1bn in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and investor in the sector. In his early career he founded the International Biochemicals Group which he sold to Royal Dutch Shell.
    Dr Michael S Perry Chief Executive Officer Feb 2013
    Mr Perry was appointed Chief Executive Officer and Executive Director in June 2017. He continues to serve in this role. Prior to this appointment, Dr Perry served as a Non-Executive Director commencing in February 2013. From 2016 to 2017, he served as Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. From 2014 to 2016, Dr Perry served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, a U.S. affiliate of Switzerland-based Novartis AG. Dr Perry previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early-stage biotech companies. He also previously served as a Venture Partner with Bay City Capital, LLC, a life science investment firm managing 41 venture capital funds, based in San Francisco California. Dr Perry serves as a Director of Arrowhead Pharmaceuticals, a public (NASDAQ) development stage company focused on medicines that treat intractable diseases by silencing genes. He is also a Venture Partner at BioScience Managers Pty Ltd.
    Ms Jan Stern Reed Non-Executive Director Jul 2021
    Jan Stern Reed has served as a Non-Executive Director since July 2021. She has more than 35 years of legal, management and business leadership experience primarily within the healthcare industry, and brings significant expertise in corporate governance, compliance and risk management. Ms. Reed served as Senior Vice President, General Counsel and Corporate Secretary at Walgreens Boots Alliance, Inc., a global pharmacy-led, health and wellbeing company. Prior to Walgreens, Ms. Reed was Executive Vice President, Human Resources, General Counsel and Corporate Secretary of Solo Cup Company, where she was responsible for the legal, human resources, internal audit, corporate communications, and compliance functions.
    Mr Cary Vance Non-Executive Director Apr 2023
    Mr Vance has over 25 years of leadership experience with commercial and operational expertise in the healthcare industry. He is currently the President and Chief Executive Officer of PhotoniCare, Inc., a position he has held since May 2023. Prior to this appointment, he was President and CEO of Titan Medical, and he continues to serve as an independent director for Titan Medical's Board of Directors. Previously, Mr. Vance served as President and CEO of XCath, a privately held neurovascular robotics company, having also served in similar roles at OptiScan Biomedical, Myoscience, and Hansen Medical.
    Mr Robert McNamara Non-Executive Director Apr 2023
    Mr McNamara is a senior executive with over 25 years of leadership experience in public and privately held companies in the medical device and technology industries. His experience in operations and financial management spans across early stage, high growth, and mature companies. He is currently a member of the Board of Directors and Chair of Audit Committee for Axonics, Inc. Additionally, Mr. McNamara is a member of the Board of Directors and Chair of Compensation Committee for Xtant Medical Holdings. Prior to these appointments, Mr. McNamara served as Executive Vice President, Chief Financial Officer of LDR Holding/Spine.
    Mr Mark Andrew Licciardo Company Secretary Mar 2018
    -
    Mr James Corbett Chief Executive OfficerPresident Jul 2021
    -
    James Corbett Chief Executive OfficerPresident
    -
    David O'Toole Chief Financial Officer
    -
    Mark Andrew Licciardo Company Secretary
    -
    Donna Shiroma General Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    UBS Nominees Pty Ltd 417,970 1.63%
    Citicorp Nominees Pty Limited 400,634 1.56%
    Washington H Soul Pattinson And Company Limited 302,529 1.18%
    BNPP Noms Pty Ltd HUB24 Custodial Serv Ltd 285,593 1.11%
    P Morgan Nominees Australia Pty Limited 204,641 0.80%
    Mr Evan Philip Clucas and Ms Leanne Jane Weston Kuranga Nursery Super A/C> 159,013 0.62%
    Hsbc Custody Nominees (Australia) Limited 122,390 0.48%
    Merrill Lynch (Australia) Nominees Pty Limited 97,530 0.38%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 92,521 0.36%
    Bnp Paribas Noms Pty Ltd 90,998 0.35%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 85,911 0.33%
    Taggart Investments Pty Ltd <Taggart Investment A/C> 76,800 0.30%
    Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> 63,116 0.25%
    Mr Eduard Avetisov 62,060 0.24%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 61,873 0.24%
    Mr Andre Wall Ellis and Mrs Olivia Louise Ellis 60,000 0.23%
    Mrs Arlene Perry 60,000 0.23%
    Wairahi Investments Limited 60,000 0.23%
    Sandhurst Trustees Ltd <Jmfg Consol A/C> 55,740 0.22%
    Mr David Anthony Deelen 50,800 0.20%

    Profile

    since

    Note